📰 Bladder Cancer Program News

Bladder Cancer Program News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Bladder Cancer Program. Real-time updates on events, politics, business and more.

AMBASSADOR: Adjuvant Pembro Boosts DFS in Urothelial Cancer

January 30, 2024

Interim findings from the ongoing AMBASSADOR trial revealed a significant DFS benefit with adjuvant pembrolizumab but no overall survival benefit at this point.

United States Johns Hopkins University Max Kates Genitourinary Malignancies Branch National Cancer Institute Drug Administration

Source: medscape.com

Cancer Conundrum: Immune Checkpoint Inhibitor Use in Transplant Recipients

January 26, 2024

Randomized clinical trials of ICIs have traditionally excluded immunocompromised individuals, but emerging evidence suggests the drugs have the potential to treat advanced cancers in transplant recipients. Clinicians face a challenge in the use of immune checkpoint inhibitor therapy in organ transplant recipients because of their need for immunosuppression.

United States New York University Of Washington Piyushk Agarwal Kenard Jhaveri Organ Procurement Transplantation Network

Source: renalandurologynews.com

UroGen Pharma - New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO in the Treatment of UTUC of the Ureter and Renal Pelvis

May 1, 2023

PRINCTON - UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a... | May 1, 2023

United States Mark Schoenberg Joseph Jacob Urogen Rtgel Bladder Cancer Program American Urological Association Meeting

Source: marketscreener.com

New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis

April 30, 2023

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis... | April 30, 2023

United States Joseph Jacob Urogen Pharma Mark Schoenberg Urogen Pharma Ltd American Urological Association Meeting

Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation